Login to Your Account


Pfizer inks new GKA development deal with China's Pegbio

By Pearl Liu
Staff Writer

Wednesday, January 11, 2017

HONG KONG – Pfizer Inc. (NYSE:PFE) will partner with Suzhou-based Pegbio Co. Ltd. to develop glucokinase activator (GKA) drugs for China as part of the multinational's strategy of using local partners to further the development of innovative drugs that address unmet needs in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription